Jan T. Christenson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jan T. Christenson has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
A Kalangos
1 shared publicationAfksendiyos Kalangos
Clinic for Cardiovascular Surgery
1 shared publicationAfksendyios Kalangos
Clinic of Cardiovascular and Thoracic Surgery, University Hospital, CH-1211 Geneva 14, Switzerland
1 shared publicationBernard Faidutti
Clinic of Cardiovascular and Thoracic Surgery, University Hospital, CH-1211 14, Geneva, Switzerland
1 shared publicationE.MAgnus Ohman
1 shared publicationFrançois Simonet
1 shared publication
Latest Publications
- 18 July 2003
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 18 (4) , 286-294
The Role of Intra-Aortic Counterpulsation in High-Risk OPCAB Surgery:
Background: High‐risk patients would benefit the most of OPCAB revascularization. This prospective and randomized study evaluates the efficacy and safety of pre‐ and perioperative IABC in ...
- 18 July 2003
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 18 (4) , 286-294
The Role of Intra-Aortic Counterpulsation in High-Risk OPCAB Surgery:
Background: High‐risk patients would benefit the most of OPCAB revascularization. This prospective and randomized study evaluates the efficacy and safety of pre‐ and perioperative IABC in ...
- 1 April 2003
- Vol. 44 (2) , 163-6
Economic impact of mitral valve plasty versus replacement for mitral valve insufficiency.
The principal techniques for surgical correction of mitral valve regurgitation (MR) were compared, with emphasis on the economic impact. In a prospective non-randomized study 225 patients undergoing mitral valve repair were analyzed, 75 had mitral valve plasty (MVP) and 150 had mitral valve replacement (MVR). Patient demographics showed no group differences. Cardiopulmonary bypass time and ischemia time were shorter in the MVP-group, p<0.0001. Hospital mortality was lower after MVP, 2.0% (3/150) compared to MVR, 6.7% (5/75). ICU-stay was shorter in the MVP-group and so was length of postoperative hospital stay, p=0.014. Urgent operation was the only significant risk factor for mortality after MVP. Re-operation, endocarditis, grade IV MR, and NYHA class IV were additional risk factors in the MVR-group. Postoperative improvements of NYHA and mitral valve function were similar in both groups. MVP was more cost effective than MVR (18,050 USD or 20,430 Euro versus 24,824 USD or 28,097 Euro, p<0.001). Mitral valve plasty for MR is efficient and associated with shorter CPB and ischemia times as well as length of stay in ICU, together with a lower device cost, which makes MVP more cost effective than MVR.
- 1 April 2003
- Vol. 44 (2) , 163-6
Economic impact of mitral valve plasty versus replacement for mitral valve insufficiency.
The principal techniques for surgical correction of mitral valve regurgitation (MR) were compared, with emphasis on the economic impact. In a prospective non-randomized study 225 patients undergoing mitral valve repair were analyzed, 75 had mitral valve plasty (MVP) and 150 had mitral valve replacement (MVR). Patient demographics showed no group differences. Cardiopulmonary bypass time and ischemia time were shorter in the MVP-group, p<0.0001. Hospital mortality was lower after MVP, 2.0% (3/150) compared to MVR, 6.7% (5/75). ICU-stay was shorter in the MVP-group and so was length of postoperative hospital stay, p=0.014. Urgent operation was the only significant risk factor for mortality after MVP. Re-operation, endocarditis, grade IV MR, and NYHA class IV were additional risk factors in the MVR-group. Postoperative improvements of NYHA and mitral valve function were similar in both groups. MVP was more cost effective than MVR (18,050 USD or 20,430 Euro versus 24,824 USD or 28,097 Euro, p<0.001). Mitral valve plasty for MR is efficient and associated with shorter CPB and ischemia times as well as length of stay in ICU, together with a lower device cost, which makes MVP more cost effective than MVR.
- 1 February 2003
- Vol. 11 (1)
Undiagnosed aberrant right subclavian artery: pitfall in aortic arch surgery.
- 1 February 2003
- Vol. 11 (1)
Undiagnosed aberrant right subclavian artery: pitfall in aortic arch surgery.
- 1 December 2002
- Published by SAGE Publications in Asian Cardiovascular and Thoracic Annals
- Vol. 10 (4) , 302-305
Preoperative Intraaortic Balloon Pump for Salvage Myocardial Revascularization
The benefit of preoperative intraaortic balloon pumping on hospital and 1-year mortality was assessed in 17 consecutive patients with cardiogenic shock who underwent salvage coronary artery bypass surgery between January 1996 and May 2000. Mean preoperative cardiac index was 1.57 ± 0 23 L.min−1.m−2. Hemodynamic stability was achieved prior to surgery in 14 patients, and mean cardiac index increased to 2.28 ± 0.64 L.min−1.m−2. Hospital mortality was 5.9% (1 patient). Five patients required postoperative intraaortic balloon pumping because of low cardiac output. The duration of intensive care, hospital stay, and the total procedural cost were similar to those reported for high-risk coronary bypass grafting. Cardiac event-free survival was 88.2% (15/17) at 1 year. Intraaortic balloon pumping promises to be an effective therapy for patients in cardiogenic shock who subsequently undergo surgical myocardial revascularization as a salvage procedure.
- 1 December 2002
- Published by SAGE Publications in Asian Cardiovascular and Thoracic Annals
- Vol. 10 (4) , 302-305
Preoperative Intraaortic Balloon Pump for Salvage Myocardial Revascularization
The benefit of preoperative intraaortic balloon pumping on hospital and 1-year mortality was assessed in 17 consecutive patients with cardiogenic shock who underwent salvage coronary artery bypass surgery between January 1996 and May 2000. Mean preoperative cardiac index was 1.57 ± 0 23 L.min−1.m−2. Hemodynamic stability was achieved prior to surgery in 14 patients, and mean cardiac index increased to 2.28 ± 0.64 L.min−1.m−2. Hospital mortality was 5.9% (1 patient). Five patients required postoperative intraaortic balloon pumping because of low cardiac output. The duration of intensive care, hospital stay, and the total procedural cost were similar to those reported for high-risk coronary bypass grafting. Cardiac event-free survival was 88.2% (15/17) at 1 year. Intraaortic balloon pumping promises to be an effective therapy for patients in cardiogenic shock who subsequently undergo surgical myocardial revascularization as a salvage procedure.
- 1 October 2002
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 74 (4) , 1086-1090
Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery
- 1 October 2002
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 74 (4) , 1086-1090
Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery
- 1 March 2002
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 73 (3) , 1026-1027
Preoperative IABP in high-risk patients reduces postoperative lactate release and subsequent mortality
- 1 March 2002
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 73 (3) , 1026-1027
Preoperative IABP in high-risk patients reduces postoperative lactate release and subsequent mortality
- 7 January 2002
- Published by SAGE Publications in Cardiovascular Surgery
- Vol. 10 (1) , 19-22
Regional extra-corporeal circulation to protect transplanted kidney and pancreas from ischemia during vascular reconstruction
The development of severe aorto-ilio-femoral atherosclerotic disease in a patient with a previous double transplantation, kidney and pancreas, is a major surgical challenge. The transplanted organs have to be protected from extensive ischemia during the vascular reconstructive procedure and achieve optimal revascularization. The surgical management of a complex case where regional extra-corporeal circulation was used to protect transplanted pancreas and kidney during aorto-bifemoral vascular grafting in a 39 yr old diabetic patient is described. Regional femoro-femoral extra-corporeal circulation with an oxygenator is a safe technique that allows time for the proximal revascularization, minimizes the warm organ ischemia time and results in preservation of organ function.
- 7 January 2002
- Published by SAGE Publications in Cardiovascular Surgery
- Vol. 10 (1) , 19-22
Regional extra-corporeal circulation to protect transplanted kidney and pancreas from ischemia during vascular reconstruction
The development of severe aorto-ilio-femoral atherosclerotic disease in a patient with a previous double transplantation, kidney and pancreas, is a major surgical challenge. The transplanted organs have to be protected from extensive ischemia during the vascular reconstructive procedure and achieve optimal revascularization. The surgical management of a complex case where regional extra-corporeal circulation was used to protect transplanted pancreas and kidney during aorto-bifemoral vascular grafting in a 39 yr old diabetic patient is described. Regional femoro-femoral extra-corporeal circulation with an oxygenator is a safe technique that allows time for the proximal revascularization, minimizes the warm organ ischemia time and results in preservation of organ function.
- 1 August 2001
- Published by SAGE Publications in Cardiovascular Surgery
- Vol. 9 (4) , 383-390
Effective surgical management of high-risk coronary patients using preoperative intra-aortic balloon counterpulsation therapy
The proportion of high-risk coronary patients submitted to surgical myocardial revascularization (CABG) is steadily increasing. High-risk patients utilize more hospital resources and have a higher procedural cost than low-moderate risk CABG patients. An efficient management is essential to improve outcome and reduce costs. This report entails three study periods. In an initial retrospective study coronary high-risk criteria were established. At least two of the following factors were required: redo CABG, unstable angina, left main stem stenosis greater than 70%, preoperative left ventricular ejection fraction < 0.30 and diffuse coronary artery disease. Poor preoperative cardiac performance was the major contributing factor for poor outcome. Intra-aortic balloon counterpulsation therapy (IABP) was introduced as preoperative therapy. During a second study period prospective randomized studies found preoperative IABP-therapy efficient, significantly improving both preoperative cardiac index (P < 0.0001), decreasing postoperative mortality (P < 0.0001) and morbidity, shorten intensive care unit stay as well as total hospital stay (P < 0.0001). Drug consumption was significantly reduced (P < 0.0001). Optimal timing was found to be 2 h prior to aortic cross-clamping and the therapy was found highly cost-beneficial with an average 36% reduction of the total procedural cost. During a third study period, well beyond any study protocol period, preoperative IABP therapy was again found highly effective with a close to 100% utilization rate in high-risk patients and continuous efficacy with excellent outcome, despite acceptance of sicker patients. During this post-study evaluation period 1/3 of the high-risk patients presented with 4 of the established risk factors. The use of preoperative IABP therapy is therefore highly recommended for high-risk coronary patients undergoing CABG.
- 1 August 2001
- Published by SAGE Publications in Cardiovascular Surgery
- Vol. 9 (4) , 383-390
Effective surgical management of high-risk coronary patients using preoperative intra-aortic balloon counterpulsation therapy
The proportion of high-risk coronary patients submitted to surgical myocardial revascularization (CABG) is steadily increasing. High-risk patients utilize more hospital resources and have a higher procedural cost than low-moderate risk CABG patients. An efficient management is essential to improve outcome and reduce costs. This report entails three study periods. In an initial retrospective study coronary high-risk criteria were established. At least two of the following factors were required: redo CABG, unstable angina, left main stem stenosis greater than 70%, preoperative left ventricular ejection fraction < 0.30 and diffuse coronary artery disease. Poor preoperative cardiac performance was the major contributing factor for poor outcome. Intra-aortic balloon counterpulsation therapy (IABP) was introduced as preoperative therapy. During a second study period prospective randomized studies found preoperative IABP-therapy efficient, significantly improving both preoperative cardiac index (P < 0.0001), decreasing postoperative mortality (P < 0.0001) and morbidity, shorten intensive care unit stay as well as total hospital stay (P < 0.0001). Drug consumption was significantly reduced (P < 0.0001). Optimal timing was found to be 2 h prior to aortic cross-clamping and the therapy was found highly cost-beneficial with an average 36% reduction of the total procedural cost. During a third study period, well beyond any study protocol period, preoperative IABP therapy was again found highly effective with a close to 100% utilization rate in high-risk patients and continuous efficacy with excellent outcome, despite acceptance of sicker patients. During this post-study evaluation period 1/3 of the high-risk patients presented with 4 of the established risk factors. The use of preoperative IABP therapy is therefore highly recommended for high-risk coronary patients undergoing CABG.
- 1 February 2001
- Published by SAGE Publications in Cardiovascular Surgery
- Vol. 9 (1) , 33-43
Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization
Hypercholesterolemia is a recognized risk factor for development of atherosclerosis in both native coronary arteries and bypass grafts. Lipid-lowering therapy with statins is effective. Few data are available for studies on bypass grafts. The influence of hypercholesterolemia on development of bypass graft disease was studied. Clinical and angiographic follow up 1yr after CABG of patients with a preoperative cholesterol >6.2mmol/l, with a preoperative lipid control (group 2) or controls (group 1) and patients with cholesterol <4.7mmol/l (group 3) were studied. Patient demographics, angiography and operation data were the same in all the groups. Group 1 patients had significantly higher incidence of graft lesions, requiring more interventions than Group 2. Sequential vein bypass grafts showed superior features compared to single vein grafts. Preoperative lipid control with statins is strongly recommended, since uncontrolled hypercholesterolemia has a direct impact on the outcome of CABG procedure. It significantly reduces the development of vein graft obstructive disease.
- 1 February 2001
- Published by SAGE Publications in Cardiovascular Surgery
- Vol. 9 (1) , 33-43
Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization
Hypercholesterolemia is a recognized risk factor for development of atherosclerosis in both native coronary arteries and bypass grafts. Lipid-lowering therapy with statins is effective. Few data are available for studies on bypass grafts. The influence of hypercholesterolemia on development of bypass graft disease was studied. Clinical and angiographic follow up 1yr after CABG of patients with a preoperative cholesterol >6.2mmol/l, with a preoperative lipid control (group 2) or controls (group 1) and patients with cholesterol <4.7mmol/l (group 3) were studied. Patient demographics, angiography and operation data were the same in all the groups. Group 1 patients had significantly higher incidence of graft lesions, requiring more interventions than Group 2. Sequential vein bypass grafts showed superior features compared to single vein grafts. Preoperative lipid control with statins is strongly recommended, since uncontrolled hypercholesterolemia has a direct impact on the outcome of CABG procedure. It significantly reduces the development of vein graft obstructive disease.
- 1 December 2000
- Published by SAGE Publications in Asian Cardiovascular and Thoracic Annals
- Vol. 8 (4) , 315-321
Preoperative Cholesterol and Thrombotic Complications after Coronary Bypass
The relationship between preoperative lipid status and postoperative thrombocytosis was evaluated in 130 patients who were grouped according to their preoperative serum cholesterol level: group A, cholesterol ≥ 6.2 mmol·L−1 (n = 40); group B, cholesterol < 6.2 but ≥ 5.2 mmol·L−1 (n = 22); group C, cholesterol < 5.2 but ≥ 4.7 (n = 18); and group D, cholesterol < 4.7 mmol·L−1 (n = 50). Patient demo-graphics, angiography findings, and operative data did not differ between the groups. The incidence of postoperative thrombocytosis (platelet count ≥ 400,000/μL) was 82.5%, 36.4%, 16.7%, and 2.0% for groups A to D, respectively. Patients who developed thrombocytosis had a significantly higher preoperative ratio of total cholesterol to high-density lipoprotein cholesterol than those with normal platelet counts. The incidence of thrombocytosis directly correlated with the preoperative total cholesterol level. A distinct separation point seems to be a total cholesterol level of 4.7 mmol·L−1. Preoperative lipid control with statins is emphasized to avoid postoperative thrombocytosis and thrombotic complications. The total cholesterol/high-density lipoprotein cholesterol ratio seems to be the best indicator of the risk of developing postoperative thrombocytosis.
- 1 December 2000
- Published by SAGE Publications in Asian Cardiovascular and Thoracic Annals
- Vol. 8 (4) , 315-321
Preoperative Cholesterol and Thrombotic Complications after Coronary Bypass
The relationship between preoperative lipid status and postoperative thrombocytosis was evaluated in 130 patients who were grouped according to their preoperative serum cholesterol level: group A, cholesterol ≥ 6.2 mmol·L−1 (n = 40); group B, cholesterol < 6.2 but ≥ 5.2 mmol·L−1 (n = 22); group C, cholesterol < 5.2 but ≥ 4.7 (n = 18); and group D, cholesterol < 4.7 mmol·L−1 (n = 50). Patient demo-graphics, angiography findings, and operative data did not differ between the groups. The incidence of postoperative thrombocytosis (platelet count ≥ 400,000/μL) was 82.5%, 36.4%, 16.7%, and 2.0% for groups A to D, respectively. Patients who developed thrombocytosis had a significantly higher preoperative ratio of total cholesterol to high-density lipoprotein cholesterol than those with normal platelet counts. The incidence of thrombocytosis directly correlated with the preoperative total cholesterol level. A distinct separation point seems to be a total cholesterol level of 4.7 mmol·L−1. Preoperative lipid control with statins is emphasized to avoid postoperative thrombocytosis and thrombotic complications. The total cholesterol/high-density lipoprotein cholesterol ratio seems to be the best indicator of the risk of developing postoperative thrombocytosis.